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We thank Drs Young and Hopkins
for their kind remarks in favor of the
American Association for Thoracic
Surgery guidelines for lung cancer
screening with low-dose chest com-
puted tomographic scans. In creating
guidelines on the basis of a successful
research protocol, the Association
chose to expand the age of the screen-
ing population beyond the ages of the
participants in the National Lung
Screening Trial.1 The rationale behind
this decision included the age distribu-
tion of the disease in North America,
the fact that increasing age is an inde-
pendent risk factor for development of
cancer, and the improvement in308 The Journal of Thoracic and Cquality life years expected up to the
9th decade of life. Drs Young and
Hopkins offer additional justification
for this guideline, namely the age-
specific lung cancer mortality in the
United States increases exponentially
after the age of 50, with a peak at the
age of 80 years.
We envision a Web-based program
that would allow each citizen to cal-
culate his or her own absolute risk
of lung cancer, dissemination of eas-
ily updated educational materials,
and potential data collection for spe-
cific populations. It is our hope that
such risk assessment would in turn
lead to risk modification and smok-
ing cessation as integrated compo-
nents of patient care. Personal risk
calculators are currently available,
but they are not easily accessible to
the public. Such a Web-based tool
might convert a guideline or instruc-
tion into a conversation between
physician and patient, including the
opportunity to further patient interest
in smoking cessation.
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EFFECTIVENESS ANALYSIS
To the Editor:
We read with interest the Canadian
cost-effectiveness analysis by Doble
and colleagues1 comparing transcath-
eter aortic valve replacement (TAVR)
with standard management (SM) for
inoperable patients and with surgical
aortic valve replacement (SAVR) for
high-risk patients with severe,ardiovascular Surgery c January 2013operable aortic stenosis. Although
we found many aspects of this work
to be well done, we believe that the
published analysis contains a few im-
portant factual errors and a few as-
sumptions that have been
contradicted by recently published
follow-up data from the PARTNER
trial.
First, the Sapien valve (Edwards
Lifesciences LLC, Irvine, Calif)
price in Doble and colleagues’ analy-
sis1 ($37,606) is $13,606 greater
than the current Canadian price of
$24,000 (all figures are in Canadian
dollars). With no other changes to
the model of Doble and colleagues,1
correction of the Sapien valve price
would make TAVR slightly cost sav-
ing (by $2453) relative to SAVR
in high-risk surgical patients and
would reduce the incremental cost-
effectiveness ratio for TAVR relative
to SM from $36,458 to $20,497
per life year gained (or from $51,324
to $29,037 per quality-adjusted life
year gained). Second, Doble and col-
leagues1 estimated the costs of
SAVR in Ontario from provincial
data for patients aged 70 years and
older in Case Mix Group (CMG)
165, cardiac valve repair. SAVR pro-
cedures are not coded under this
CMG in Ontario, however, but rather
under CMG 162 (cardiac valve re-
placement), which has slightly higher
reimbursement. More importantly,
we believe that ‘‘average’’ reimburse-
ment values for SAVR in patients aged
70 years and older are likely to under-
estimate the true costs of SAVR
among patients like those in the
PARTNER trial, whose baseline char-
acteristics in the clinical trial placed
them in the highest 5% to 10% of
predicted operative risk.2
In projecting survival for inopera-
ble patients, Doble and colleagues1
used Canadian life table data for years
2 through 20 of their model for both
TAVR and SM patient cohorts. This
approach assumes that survivals be-
yond 1 year would be similar for the
two groups, in essence ignoring the
